Monday, September 22, 2014
Inquirer Daily News

Pfizer-Wyeth merger won't likely benefit R&D, consumers: report

Will the planned $63 billion Pfizer-Wyeth merger be a test case for the revival of antitrust enforcement in the U.S. under President Obama?

Pfizer-Wyeth merger won't likely benefit R&D, consumers: report

Will the planned $63 billion Pfizer-Wyeth merger be a test case for the revival of antitrust enforcement in the U.S. under President Obama?

"That the merger of Pfizer with Wyeth will benefit consumers is far from a foregone conclusion,"  says this paper, written by former Federal Trade Commission economists William Comanor (now of Harvard) and F.M. Scherer (UCLA) and sent to Attorney General Eric Holder by the American Antitrust Institute, Washington, DC.

 "There is ample reason to believe that it will make an unsatisfactory bureaucratic situation even worse, while it enriches the company managers and the banks that allocate funds from the merger... A careful and skeptical investigation by the responsible antitrust agency is very much in the national interest."

About this blog

PhillyDeals posts raw drafts and updates of Joseph N. DiStefano's columns and stories about Philly-area finance, investment, commercial real estate, tech, hiring and public spending, which he's been writing since 1989, mostly for the Philadelphia Inquirer.

DiStefano studied economics, history and a little engineering at Penn, taught writing at St. Joe's, and has written the book Comcasted, more than a thousand columns, and thousands of articles, and raised six children with his wife, who is a saint.

Reach Joseph N. at JoeD@phillynews.com or 215 854 5194.

Joseph N. DiStefano
Business Videos:
Also on Philly.com:
Stay Connected